Bladder cancer, version 5.2017

Clinical practice guidelines in oncology

Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Peter E. Clark, Tracy M. Downs, Jason A. Efstathiou, Thomas W. Flaig, Terence Friedlander, Richard E. Greenberg, Khurshid A. Guru, Noah Hahn, Harry W. Herr, Christopher Hoimes, Brant A. Inman, Masahito Jimbo, A. Karim Kader, Subodh M. Lele, Joshua J. Meeks & 16 others Jeff Michalski, Jeffrey S. Montgomery, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Mark A. Preston, Wade J. Sexton, Arlene O. Siefker-Radtke, Guru Sonpavde, Jonathan Tward, Geoffrey Wile, Mary A. Dwyer, Lisa A. Gurski

Research output: Contribution to journalReview article

66 Citations (Scopus)

Abstract

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on systemic therapy for muscle-invasive urothelial bladder cancer, as substantial revisions were made in the 2017 updates, such as new recommendations for nivolumab, pembrolizumab, at-ezolizumab, durvalumab, and avelumab. The complete version of the NCCN Guidelines for Bladder Cancer addresses additional aspects of the management of bladder cancer, including non-muscle-invasive urothelial bladder cancer and nonurothelial histologies, as well as staging, evaluation, and follow-up.

Original languageEnglish (US)
Pages (from-to)1240-1267
Number of pages28
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume15
Issue number10
DOIs
StatePublished - Oct 1 2017

Fingerprint

Practice Guidelines
Urinary Bladder Neoplasms
Guidelines
Histology
Muscles
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Spiess, P. E., Agarwal, N., Bangs, R., Boorjian, S. A., Buyyounouski, M. K., Clark, P. E., ... Gurski, L. A. (2017). Bladder cancer, version 5.2017: Clinical practice guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network, 15(10), 1240-1267. https://doi.org/10.6004/jnccn.2017.0156

Bladder cancer, version 5.2017 : Clinical practice guidelines in oncology. / Spiess, Philippe E.; Agarwal, Neeraj; Bangs, Rick; Boorjian, Stephen A.; Buyyounouski, Mark K.; Clark, Peter E.; Downs, Tracy M.; Efstathiou, Jason A.; Flaig, Thomas W.; Friedlander, Terence; Greenberg, Richard E.; Guru, Khurshid A.; Hahn, Noah; Herr, Harry W.; Hoimes, Christopher; Inman, Brant A.; Jimbo, Masahito; Kader, A. Karim; Lele, Subodh M.; Meeks, Joshua J.; Michalski, Jeff; Montgomery, Jeffrey S.; Pagliaro, Lance C.; Pal, Sumanta K.; Patterson, Anthony; Plimack, Elizabeth R.; Pohar, Kamal S.; Porter, Michael P.; Preston, Mark A.; Sexton, Wade J.; Siefker-Radtke, Arlene O.; Sonpavde, Guru; Tward, Jonathan; Wile, Geoffrey; Dwyer, Mary A.; Gurski, Lisa A.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 15, No. 10, 01.10.2017, p. 1240-1267.

Research output: Contribution to journalReview article

Spiess, PE, Agarwal, N, Bangs, R, Boorjian, SA, Buyyounouski, MK, Clark, PE, Downs, TM, Efstathiou, JA, Flaig, TW, Friedlander, T, Greenberg, RE, Guru, KA, Hahn, N, Herr, HW, Hoimes, C, Inman, BA, Jimbo, M, Kader, AK, Lele, SM, Meeks, JJ, Michalski, J, Montgomery, JS, Pagliaro, LC, Pal, SK, Patterson, A, Plimack, ER, Pohar, KS, Porter, MP, Preston, MA, Sexton, WJ, Siefker-Radtke, AO, Sonpavde, G, Tward, J, Wile, G, Dwyer, MA & Gurski, LA 2017, 'Bladder cancer, version 5.2017: Clinical practice guidelines in oncology', JNCCN Journal of the National Comprehensive Cancer Network, vol. 15, no. 10, pp. 1240-1267. https://doi.org/10.6004/jnccn.2017.0156
Spiess, Philippe E. ; Agarwal, Neeraj ; Bangs, Rick ; Boorjian, Stephen A. ; Buyyounouski, Mark K. ; Clark, Peter E. ; Downs, Tracy M. ; Efstathiou, Jason A. ; Flaig, Thomas W. ; Friedlander, Terence ; Greenberg, Richard E. ; Guru, Khurshid A. ; Hahn, Noah ; Herr, Harry W. ; Hoimes, Christopher ; Inman, Brant A. ; Jimbo, Masahito ; Kader, A. Karim ; Lele, Subodh M. ; Meeks, Joshua J. ; Michalski, Jeff ; Montgomery, Jeffrey S. ; Pagliaro, Lance C. ; Pal, Sumanta K. ; Patterson, Anthony ; Plimack, Elizabeth R. ; Pohar, Kamal S. ; Porter, Michael P. ; Preston, Mark A. ; Sexton, Wade J. ; Siefker-Radtke, Arlene O. ; Sonpavde, Guru ; Tward, Jonathan ; Wile, Geoffrey ; Dwyer, Mary A. ; Gurski, Lisa A. / Bladder cancer, version 5.2017 : Clinical practice guidelines in oncology. In: JNCCN Journal of the National Comprehensive Cancer Network. 2017 ; Vol. 15, No. 10. pp. 1240-1267.
@article{1172e074b6e64796ba2793f44b6bfc35,
title = "Bladder cancer, version 5.2017: Clinical practice guidelines in oncology",
abstract = "This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on systemic therapy for muscle-invasive urothelial bladder cancer, as substantial revisions were made in the 2017 updates, such as new recommendations for nivolumab, pembrolizumab, at-ezolizumab, durvalumab, and avelumab. The complete version of the NCCN Guidelines for Bladder Cancer addresses additional aspects of the management of bladder cancer, including non-muscle-invasive urothelial bladder cancer and nonurothelial histologies, as well as staging, evaluation, and follow-up.",
author = "Spiess, {Philippe E.} and Neeraj Agarwal and Rick Bangs and Boorjian, {Stephen A.} and Buyyounouski, {Mark K.} and Clark, {Peter E.} and Downs, {Tracy M.} and Efstathiou, {Jason A.} and Flaig, {Thomas W.} and Terence Friedlander and Greenberg, {Richard E.} and Guru, {Khurshid A.} and Noah Hahn and Herr, {Harry W.} and Christopher Hoimes and Inman, {Brant A.} and Masahito Jimbo and Kader, {A. Karim} and Lele, {Subodh M.} and Meeks, {Joshua J.} and Jeff Michalski and Montgomery, {Jeffrey S.} and Pagliaro, {Lance C.} and Pal, {Sumanta K.} and Anthony Patterson and Plimack, {Elizabeth R.} and Pohar, {Kamal S.} and Porter, {Michael P.} and Preston, {Mark A.} and Sexton, {Wade J.} and Siefker-Radtke, {Arlene O.} and Guru Sonpavde and Jonathan Tward and Geoffrey Wile and Dwyer, {Mary A.} and Gurski, {Lisa A.}",
year = "2017",
month = "10",
day = "1",
doi = "10.6004/jnccn.2017.0156",
language = "English (US)",
volume = "15",
pages = "1240--1267",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "10",

}

TY - JOUR

T1 - Bladder cancer, version 5.2017

T2 - Clinical practice guidelines in oncology

AU - Spiess, Philippe E.

AU - Agarwal, Neeraj

AU - Bangs, Rick

AU - Boorjian, Stephen A.

AU - Buyyounouski, Mark K.

AU - Clark, Peter E.

AU - Downs, Tracy M.

AU - Efstathiou, Jason A.

AU - Flaig, Thomas W.

AU - Friedlander, Terence

AU - Greenberg, Richard E.

AU - Guru, Khurshid A.

AU - Hahn, Noah

AU - Herr, Harry W.

AU - Hoimes, Christopher

AU - Inman, Brant A.

AU - Jimbo, Masahito

AU - Kader, A. Karim

AU - Lele, Subodh M.

AU - Meeks, Joshua J.

AU - Michalski, Jeff

AU - Montgomery, Jeffrey S.

AU - Pagliaro, Lance C.

AU - Pal, Sumanta K.

AU - Patterson, Anthony

AU - Plimack, Elizabeth R.

AU - Pohar, Kamal S.

AU - Porter, Michael P.

AU - Preston, Mark A.

AU - Sexton, Wade J.

AU - Siefker-Radtke, Arlene O.

AU - Sonpavde, Guru

AU - Tward, Jonathan

AU - Wile, Geoffrey

AU - Dwyer, Mary A.

AU - Gurski, Lisa A.

PY - 2017/10/1

Y1 - 2017/10/1

N2 - This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on systemic therapy for muscle-invasive urothelial bladder cancer, as substantial revisions were made in the 2017 updates, such as new recommendations for nivolumab, pembrolizumab, at-ezolizumab, durvalumab, and avelumab. The complete version of the NCCN Guidelines for Bladder Cancer addresses additional aspects of the management of bladder cancer, including non-muscle-invasive urothelial bladder cancer and nonurothelial histologies, as well as staging, evaluation, and follow-up.

AB - This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on systemic therapy for muscle-invasive urothelial bladder cancer, as substantial revisions were made in the 2017 updates, such as new recommendations for nivolumab, pembrolizumab, at-ezolizumab, durvalumab, and avelumab. The complete version of the NCCN Guidelines for Bladder Cancer addresses additional aspects of the management of bladder cancer, including non-muscle-invasive urothelial bladder cancer and nonurothelial histologies, as well as staging, evaluation, and follow-up.

UR - http://www.scopus.com/inward/record.url?scp=85030858287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030858287&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2017.0156

DO - 10.6004/jnccn.2017.0156

M3 - Review article

VL - 15

SP - 1240

EP - 1267

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 10

ER -